| HIV Infections
Cabenuva vs Truvada
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Cabenuva vs Truvada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruvada has a higher rate of injection site reactions vs Cabenuva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truvada but not Cabenuva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cabenuva
Truvada
At A Glance
IM injection (gluteal)
Every 4 weeks or every 8 weeks
INSTI + NNRTI combination
Oral
Once daily
NRTI combination (FTC + TDF)
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections (Monthly Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in; Continuation: cabotegravir 400 mg IM + rilpivirine 600 mg IM every month thereafter. Separate gluteal injection sites required.
HIV Infections (Every 2-Month Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in, repeated 1 month later; Continuation: cabotegravir 600 mg IM + rilpivirine 900 mg IM every 2 months thereafter. Separate gluteal injection sites required.
HIV Infections Adults and pediatric patients weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; pediatric patients weighing 17 to <35 kg: weight-based lower-strength tablet (100 mg/150 mg, 133 mg/200 mg, or 167 mg/250 mg) once daily; CrCl 30-49 mL/min: one tablet every 48 hours; CrCl <30 mL/min or hemodialysis: not recommended.
HIV-1 Pre-Exposure Prophylaxis HIV-1 uninfected adults and adolescents weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; not recommended if CrCl <60 mL/min.
Contraindications
- Previous hypersensitivity reaction to cabotegravir or rilpivirine
- Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (anticonvulsants)
- Rifabutin, rifampin, rifapentine (antimycobacterials)
- Dexamethasone (systemic, more than single dose)
- St. John's wort (Hypericum perforatum)
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
Adverse Reactions
Most common (>=2%) Injection site reactions (pain/discomfort, nodules, induration, swelling, erythema, pruritus, bruising/discoloration, warmth, hematoma), pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash
Serious Hypersensitivity reactions including angioedema and urticaria, hepatotoxicity, depression and suicidal ideation/attempt, severe skin reactions including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis
Postmarketing Hypersensitivity reactions, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=10%) Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash
Serious Severe acute exacerbations of hepatitis B, new onset or worsening renal impairment, immune reconstitution syndrome, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Allergic reaction including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, hepatic steatosis, hepatitis, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, proteinuria, asthenia
Pharmacology
Cabotegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step essential for HIV replication. Rilpivirine is an NNRTI that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
FTC and TDF are both nucleoside analog reverse transcriptase inhibitors (NRTIs); each is converted intracellularly to an active triphosphate form that inhibits HIV-1 reverse transcriptase by competing with natural dNTP substrates and causing chain termination. No antagonism between FTC and TDF has been observed in cell culture combination studies.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cabenuva
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Truvada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cabenuva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Truvada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Cabenuva
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Truvada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Cabenuva Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CabenuvaView full Cabenuva profile
TruvadaView full Truvada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.